Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/ FUS‐ERG and early relapse after allogeneic blood stem cell transplantation: A case report

Acute myeloid leukemia (AML) with FUS‐ERG has a poor prognosis regardless of allo‐hematopoietic stem cell transplantation (HSCT). Maintenance therapy such as azacitidine after allo‐HSCT for AML with FUS‐ERG may be clinically meaningful.